NCT00859469 · OUTCOME

Progression-free Survival

Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma · Source last updated 2019-10-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: 50 months

What was measured

Time to radiologic disease progression or death

Groups in this outcome

Oxaliplatin and Gemcitabine

The study drugs will be administered in the following manner: Gemcitabine, at 1000 mg/m² IV infusion over 90 minutes, then Oxaliplatin, at 100 mg/m² IV infusion over 2 hours.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Oxaliplatin and Gemcitabine	29

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Oxaliplatin and Gemcitabine	5	Not reported	2	7	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
2
upper Limit
7
value
5

denoms

counts
group Id
OG000
value
29
units
Participants

description

Time to radiologic disease progression or death

dispersion Type

95% Confidence Interval

groups

description
The study drugs will be administered in the following manner: Gemcitabine, at 1000 mg/m² IV infusion over 90 minutes, then Oxaliplatin, at 100 mg/m² IV infusion over 2 hours.
id
OG000
title
Oxaliplatin and Gemcitabine

param Type

MEDIAN

reporting Status

POSTED

time Frame

50 months

title

Progression-free Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice